Subsequent Event	9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent event	Note 13. Subsequent event BVF Agreement In the fourth quarter of 2021, the Company and BVF Partners L.P. (BVF) entered into an agreement (the BVF Agreement) under which BVF will pay up to $15 million to the Company for the discovery and development of compounds for the treatment of inflammatory diseases (the Program). The Company received $5 million from BVF in the fourth quarter of 2021. In return, the Company is obligated to make milestone payments upon the achievement of certain clinical and regulatory milestones and will pay royalties based on net sales of products generated by the Program. The agreement also provides BVF with the option to provide an additional $10 million in funding for the Program in exchange for an increase in the royalty rate. Consistent with the terms of the Gilead Collaboration Agreement, Gilead has an option to the Program.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration